In GLORY-1, mazdutide 6 mg produced mean body-weight change of approximately negative 15 percent versus negative 0.5 percent with placebo at 48 weeks. The placebo-subtracted treatment difference was approximately negative 14 percentage points. Orforglipron 36 mg achieved approximately negative 12 percent at 72 weeks in ATTAIN-1 but no head-to-head RCT between the two agents exists.
What Mechanistic Rationale Distinguishes GLP-1/Glucagon Dual Agonism From GLP-1 Monotherapy?
Mazdutide co-activates the GLP-1 receptor and the glucagon receptor within a single peptide scaffold. GLP-1R engagement drives appetite suppression and glucose-dependent insulin secretion. GCGR co-activation adds increased resting energy expenditure, hepatic lipid oxidation, and thermogenic signalling that GLP-1 monotherapy does not reliably produce.
The glucagon receptor's contribution to weight loss operates through at least three pathways mechanistically distinct from GLP-1R signalling. GCGR activation in the liver stimulates fatty acid oxidation and suppresses lipogenesis. In brown adipose tissue glucagon signalling upregulates uncoupling protein-1 expression and increases thermogenic capacity. Hypothalamic GCGR activation independently reduces food intake through pathways that partially overlap with GLP-1R-mediated satiety signalling.
The theoretical risk of GCGR co-activation is hyperglycaemia because glucagon is a counter-regulatory hormone that raises hepatic glucose output. Mazdutide's clinical design addresses this by calibrating the GLP-1R-to-GCGR activity ratio so that GLP-1R-mediated insulin secretion dominates the glycaemic axis. Phase 2 data confirmed that mazdutide did not produce net hyperglycaemia at therapeutic doses.
This mechanistic architecture distinguishes mazdutide from tirzepatide and retatrutide. Tirzepatide's second receptor is the GIP receptor which modulates insulin secretion and adipose lipid storage but does not drive the thermogenic energy-expenditure axis that glucagon receptor activation provides. The receptor pharmacology therefore predicts a qualitatively different weight-loss mechanism rather than merely a quantitative increment.
What Did the GLORY-1 Phase 3 Trial Show for Mazdutide Versus Placebo in Obesity?
GLORY-1 randomised 610 Chinese adults with obesity or overweight to mazdutide 4 mg or 6 mg or placebo once weekly for 48 weeks. Mean body-weight change was negative 12 percent at 4 mg and negative 15 percent at 6 mg versus negative 0.5 percent with placebo. The placebo-subtracted treatment difference for the 6 mg dose was negative 14 percentage points.
At week 32 the proportion of participants achieving at least 5 percent weight reduction was approximately 76 percent in the 6 mg group versus approximately 7 percent with placebo. At the 6 mg dose approximately half of participants achieved at least 15 percent body-weight reduction by week 48. The 4 mg dose produced a treatment difference of approximately negative 12 percentage points versus placebo.
The primary endpoint in GLORY-1 was mean percentage body-weight change from baseline to week 32 with week 48 data as a secondary endpoint. The trial enrolled Chinese adults with a mean baseline BMI of approximately 31 which is substantially lower than the mean of approximately 38 in STEP 1 and ATTAIN-1. This difference in baseline adiposity complicates direct numerical comparison across trials.
Cardiometabolic secondary endpoints in GLORY-1 showed dose-proportional improvements in waist circumference, systolic blood pressure, fasting triglycerides, and fasting glucose. These findings are consistent with the dual GLP-1R/GCGR mechanism where hepatic lipid oxidation and energy expenditure augment the cardiometabolic benefits attributable to weight loss alone.
How Did Mazdutide Perform Against Semaglutide 1 mg in the DREAMS-3 Head-to-Head Phase 3 Trial?
DREAMS-3 randomised Chinese adults with T2D and obesity to mazdutide 6 mg or semaglutide 1 mg once weekly. At week 32 mean body-weight change was approximately negative 10 percent with mazdutide versus negative 6 percent with semaglutide. The composite primary endpoint was achieved by 48 percent on mazdutide versus approximately 20 percent on semaglutide.
The composite primary endpoint required both HbA1c below 7 percent and at least 10 percent weight reduction in the same participant. The HbA1c reduction from baseline reached approximately negative 2 percent with mazdutide versus approximately negative 2 percent with semaglutide establishing statistical superiority on both axes. The DREAMS-3 comparator was semaglutide 1 mg rather than the 2.4 mg obesity dose used in STEP 1.
This dose selection reflects the T2D indication context but means the weight-loss comparison is not against semaglutide's maximum anti-obesity dose. The 48 percent composite responder rate with mazdutide versus approximately 20 percent with semaglutide 1 mg represents a clinically meaningful separation on a dual-outcome metric. Requiring simultaneous achievement of both glycaemic control and weight loss is a more demanding criterion than either endpoint alone.
Innovent Biologics received NMPA approval for mazdutide in the T2D indication in 2025 based in part on the DREAMS programme data. Mazdutide had previously received NMPA approval for chronic weight management in adults with overweight or obesity. Neither approval extends to regulatory jurisdictions outside China and no FDA or EMA filing has been announced as of mid-2026.
What Did the ATTAIN-1 Phase 3 Trial Establish for Orforglipron in Obesity?
ATTAIN-1 randomised adults with obesity to orforglipron 12 mg or 24 mg or 36 mg once daily or placebo for 72 weeks. The 36 mg dose produced mean body-weight reduction of approximately negative 12 percent versus approximately negative 1 percent with placebo. All three doses met the primary and key secondary endpoints.
Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist that achieves oral bioavailability without absorption enhancers and requires no food or water restrictions at administration. Its mechanism is GLP-1R monotherapy and it does not engage the glucagon receptor. The 72-week ATTAIN-1 duration is longer than GLORY-1's 48-week primary endpoint which limits direct percentage-point comparison between the two agents.
The dose-response relationship in ATTAIN-1 was steep with the 12 mg dose producing approximately 8 percent weight loss and the 24 mg dose approximately 11 percent. The 36 mg dose reached approximately negative 12 percent at 72 weeks. This gradient suggests that higher doses may produce greater weight loss and the approved dose range has not yet been established by regulatory agencies.
The ATTAIN-1 population had a mean baseline BMI of approximately 37 to 38 which is substantially higher than the GLORY-1 population mean of approximately 31. Higher baseline BMI is associated with larger absolute weight-loss percentages in GLP-1 receptor agonist trials. This population difference is a confounding variable when comparing the two agents' results across trials.
What Do the Cross-Trial Efficacy Numbers Actually Allow Researchers to Conclude?
Cross-trial comparison between GLORY-1 and ATTAIN-1 is structurally limited by three non-trivial differences. GLORY-1 used a 48-week endpoint versus ATTAIN-1's 72 weeks. GLORY-1 enrolled a Chinese population with mean BMI approximately 31 versus ATTAIN-1's Western population at approximately 37 to 38 and the two agents act at different receptor combinations. These differences preclude any efficacy ranking.
Weight loss with GLP-1 receptor agonists continues to accumulate beyond 48 weeks in most trials before reaching a plateau. The STEP 1 trial with subcutaneous semaglutide showed continued weight loss from week 48 to week 68. If mazdutide's trajectory follows a similar pattern the 48-week GLORY-1 figure likely underestimates the 72-week outcome.
The population difference is equally important. Lower baseline BMI in Chinese adults enrolled in GLORY-1 means the absolute weight-loss percentage is not directly comparable to trials in higher-BMI Western populations. Normalising for baseline BMI using regression modelling would be required to generate a meaningful cross-trial estimate and no such analysis has been published for the mazdutide-orforglipron comparison.
The mechanistic difference between dual GLP-1R/GCGR agonism for mazdutide and GLP-1R monotherapy for orforglipron means that even a properly controlled head-to-head trial would be comparing pharmacologically distinct agents. The absence of a direct RCT is therefore not simply a methodological gap. It reflects the fact that no such comparison has been designed or initiated.
What Does the Phase 3 Safety Data Show for Mazdutide Across the GLORY and DREAMS Programmes?
Across the GLORY-1 and DREAMS programme trials mazdutide's safety profile is dominated by gastrointestinal adverse events including nausea, diarrhoea, and vomiting predominantly mild to moderate in severity and concentrated during dose escalation. No new safety signals were identified in DREAMS-3 relative to earlier studies. The overall profile is consistent with the GLP-1 receptor agonist class.
In GLORY-1 gastrointestinal adverse events were the most frequently reported treatment-emergent events across both dose groups. The incidence was higher during the titration phase and attenuated after reaching the maintenance dose, a pattern consistent with GLP-1 receptor agonist class pharmacology. Discontinuation due to adverse events was not reported at rates substantially exceeding those observed in comparable GLP-1 monotherapy trials.
The GCGR component of mazdutide's mechanism raises a theoretical concern about hepatic glucose output and cardiovascular effects of glucagon receptor activation. Phase 3 data did not identify clinically significant hyperglycaemia attributable to GCGR agonism consistent with the pharmacological design rationale that GLP-1R-mediated insulin secretion offsets glucagon's glycaemic effect. Cardiovascular outcomes data for mazdutide are not available from the current phase 3 programme.
No cardiovascular outcomes trial for mazdutide has been announced or initiated as of mid-2026. The absence of CVOT data is a material evidence gap for any regulatory submission outside China. Semaglutide's cardiovascular benefit in obesity was established by the SELECT trial and no equivalent evidence exists for mazdutide or for orforglipron.
What Are the Critical Evidence Gaps That Constrain Interpretation of Mazdutide's Phase 3 Data in 2026?
Four gaps define the interpretive limits of mazdutide's 2026 evidence base. There is no head-to-head RCT against orforglipron or any GLP-1 monotherapy at equivalent obesity doses. There are no 72-week obesity data, no cardiovascular outcomes trial, and no data in non-Chinese populations. NMPA approvals confirm regulatory sufficiency within China but do not resolve these gaps for global interpretation.
The population specificity of the GLORY-1 and DREAMS programme data is a structural limitation that cannot be resolved by re-analysis. Chinese adults with obesity have a lower mean BMI threshold for metabolic comorbidities than Western populations and pharmacogenomic differences in drug metabolism cannot be excluded. Bridging studies in non-Asian populations would be required before extrapolating GLORY-1 efficacy estimates to Western clinical contexts.
The 48-week primary endpoint in GLORY-1 is shorter than the 68 to 72-week endpoints used in STEP 1, SURMOUNT-1, and ATTAIN-1. This duration difference is not trivial as weight-loss trajectories with GLP-1-based agents typically have not plateaued by week 48. The GLORY-1 figure therefore represents a point-in-time snapshot rather than a steady-state efficacy estimate.
Lean mass preservation during mazdutide-induced weight loss has not been reported as a pre-specified endpoint in the published phase 3 data. This is a clinically relevant gap given that GLP-1 receptor agonist-induced weight loss includes a lean mass component that varies across agents and populations. Comparative body composition data across the GLP-1/GCGR dual agonist class versus GLP-1 monotherapy would be required to determine whether the GCGR axis confers any lean mass advantage.
How Are GLP-1/Glucagon Dual Agonist Protocols Structured for Safety in Clinical Practice in 2026? | How Do GLP-1/Glucagon Dual Agonists Interact With Dietary Patterns and Body Composition in 2026? | What Does the 2026 Clinical Monograph on Mazdutide Reveal About Its Mechanism, Studied Doses, and Regulatory Status? Does Retatrutide's Triple-Receptor Mechanism Produce Greater Fat-Mass Reduction Than Semaglutide or Tirzepatide Under Equal Calorie and Exercise Conditions in 2026? What Does 2026 Research Show About Semaglutide's Role in Metabolic Medicine? How Does Retatrutide's Triple Agonist Activity at GLP-1, GIP, and Glucagon Receptors Change Protocol Design for Weight Loss Versus Dual Agonists in 2026?